Business Wire

Reopening of Black Sea a welcome relief, but while Ukraine remains volatile, latest data shows industry adapting

Share

With news of last week’s UN deal to reopen the Black Sea, allowing ocean grain shipments to resume from Ukraine, leading real-time supply chain visibility platform FourKites® released new data showing that agile shippers are finding ways of managing the volatile situation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005468/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites data shows increased shipments to countries bordering Russia and Ukraine (Graphic: Business Wire)

Following Friday’s grain deal between Ukraine and Russia, FourKites expects grain shipments from Black Sea ports to resume within a few days. The same deal allows Russia to export fertiliser and other products not covered by international sanctions.

“My hope is that this agreement gives big shipping companies the confidence to resume operations in the region,” says Philippe Salles, FourKites’ VP Strategic Solutions (Ocean). “The next few weeks will be telling. But if things go well, this deal could be central to averting a worldwide food crisis. And despite the latest missile attack at the port of Odessa, indicating ongoing volatility in the region, our data indicates that shippers are well prepared for any contingency.”

Ukraine typically ships millions of tonnes of grain by ocean direct from its Black Sea ports to countries including Egypt, Indonesia and Bangladesh. The war effectively closed that route, as major shipping companies concluded it was too dangerous to operate in the Black Sea. Now, it is hoped, at least some of those shipments can resume.

“Our data for the last few weeks shows that logistics operators were already adapting to the situation in Ukraine,” says Salles. “Ukrainian shippers have been shifting to road and rail to move grain to sea ports outside the country, notably in Poland or via the Balkans to Adriatic ports such as Trieste and Rijeka.”

Shipments of all types to countries bordering Russia and Ukraine remain strong compared to the rest of Europe, where the 14-day average shipment volume is up 20% compared to 21 February, when the invasion began. At the same time, less than truckload (LTL) delays to Eastern Europe have decreased over the past few weeks, with delayed LTL shipments now only 15% higher than when the conflict began. This is down 48% month-on-month compared to mid-June, when LTL delays were as much as 33% higher than when the conflict began.

Prior to the UN deal, hundreds of thousands of tonnes of grain were destined to travel by longer land routes, which raised questions about whether there would be sufficient capacity to provide the thousands of additional truck journeys that would be needed.

“Ukrainian carriers are going full throttle to export grain and revive the country’s economic growth,” comments Maciej Mackowiak, FourKites’ Director, Carrier Marketing, Europe, who is based in Poland. “We are already seeing a lot of congestion on the Polish/Ukraine border because, since mid-July, the European Union has allowed Ukrainian road transport companies to make shipments without permits.”

Overall, moving goods into or out of Ukraine remains difficult. Shipment volumes to Ukraine have recovered slightly from their nadir in March, but are still 65% down on pre-war levels.

About FourKites

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
European PR Director, FourKites
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye